doi: 10.3389/fpls.2025.1694779 Received 28 August 2025 Accepted 14 October 2025 Published 17 November 2025 Volume 16 - 2025 Edited by Saif Ali, CAB International, Pakistan Reviewed by Imran Ul Haq, University of Agriculture, Faisalabad, Pakistan Ali Hassan, Hubei University, China Muhammad Faisal, University of Agriculture, Pakistan Updates Copyright 2025 Umer, Naseer, Mubeen, Iftikhar, Umer, Akram, Altaf, Ibrahim, Ahmed and Duan
Treatment Treatment depends on your needs
CagriSema is a two-peptide fixed combination the amylin analogue cagrilintide co-administered with the GLP-1 receptor agonist semaglutide whereas tirzepatide is a single engineered molecule that activates two receptors (GIP and GLP-1) at once
Acknowledgements Figures created with BioRender.com